Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
| 5.79 | |
| 6 | |
| - | |
| 6 | |
| 5.7 | |
| 1.66-6.72 | |
| 329 M | |
| 42 079 K | |
| 0 | |
| -0.42 | |
| 1.54 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Key Insights Given the large stake in the stock by institutions, Prelude Therapeutics' stock price might be vulnerable to their trading decisions The top 2 shareholders own 54% of the company Ownersh...
Shell plc SHEL confirmed the recommencement of liquefied natural gas (LNG) cargo loading from its offshore Prelude facility in Australia. The colossal floating LNG production facility, located approxi...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
